Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03240315|
Recruitment Status : Enrolling by invitation
First Posted : August 7, 2017
Last Update Posted : December 3, 2018
|Condition or disease|
|Pulmonary Disease, Chronic Obstructive|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Establishment of Individualized Prediction System for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Based on Cloud Platform|
|Actual Study Start Date :||August 1, 2016|
|Estimated Primary Completion Date :||August 2020|
|Estimated Study Completion Date :||December 2020|
Subjects with GOLD stage I-IV COPD
- Establishment of prediction platform for COPD exacerbation [ Time Frame: 3 years ]The patients with chronic obstruction pulmonary disease will be followed up at intervals of 3 months for 3 years by the Modified British Medical Research Council (mMRC) score scale,spirometric analysis, sputum smear,questionnaire and so on. An exacerbation of COPD was diagnosed according to GOLD guidelines. Time to the first acute exacerbation and average number of acute exacerbations per year in COPD subjects will be record.Research of AECOPD Risk factors based on complex network analysis.Identification and validation of COPD exacerbations risk stratification and predictive markers based on data mining.
- Developing new protein chips for AECOPD [ Time Frame: 3 years ]Systemic and airway autoantibody profiles and cytokine profiles will be measured using commercial multiplex bead-based assay to screen out a set of ideal AECOPD-related markers.
- Detection of immune repertoire in COPD/AECOPD [ Time Frame: 3 years ]Immune status of COPD patients will be investigated by using the immune repertoire technique and its relationship with the pathophysiology of AECOPD will be identified.
- Pathogenic microorganism and drug resistance monitoring for COPD exacerbation [ Time Frame: 3 years ]Dynamics of pathogenic microorganism and drug resistance in natural course of COPD will be investigated by using the metagenome technique and the culture technique.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03240315
|Guangzhou Institute of Respiratory Disease,The First Affiliated Hospital of Guangzhou Medical University|
|Guangzhou, Guangdong, China, 510120|
|Study Director:||Rongchang Chen, MD/Ph.D||Guangzhou Institute of Respiratory Disease,The First Affiliated Hospital of Guangzhou Medical University,China|